Supplementing Conventional Treatment with Pycnogenol® May Improve Hepatitis C Virus–Associated Type 2 Diabetes: A Mini Review

Hepatitis C virus (HCV) infection and type 2 diabetes mellitus (T2DM) present a significant health burden, with increasing complications and mortality rates worldwide. Pycnogenol® (PYC), a natural product, possesses antidiabetic and antiviral properties that may improve HCV-associated T2DM. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Ezzikouri, Sayeh, Jadid, Fatima Zahra, Hamdi, Salsabil, Wakrim, Lahcen, Tsukiyama-Kohara, Kyoko, Benjelloun, Soumaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075005/
https://www.ncbi.nlm.nih.gov/pubmed/27777890
http://dx.doi.org/10.14218/JCTH.2016.00021
Descripción
Sumario:Hepatitis C virus (HCV) infection and type 2 diabetes mellitus (T2DM) present a significant health burden, with increasing complications and mortality rates worldwide. Pycnogenol® (PYC), a natural product, possesses antidiabetic and antiviral properties that may improve HCV-associated T2DM. In this review, we present previously published data on the effectiveness of PYC against HCV replication and T2DM. We believe that supplementing conventional treatment with PYC may improve the current HCV therapy, attenuate HCV-associated T2DM, and reduce the risk of complications such as cirrhosis or hepatocellular carcinoma and cardiovascular disease.

Ejemplares similares